Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO"), effective December 9th, 2024, according to the announcement issued by Hang Seng Indexes Company Limited ("HSIL").
()
香港，2024年12月3日 /PRNewswire/ -- 方舟健客(临时代码)（"方舟"或"公司"）（06086.HK），互联网医疗保健解决方案的领导者，今日宣布，根据恒生指数有限公司（"HSIL"）发布的公告，公司在香港联合交易所（"香港交易所"）的普通股将于2024年12月9日起被纳入恒生香港上市生物科技指数（"HSHKBIO"）
()
Mr. Xie Fangmin, Chairman and CEO of Fangzhou, stated, "We are thrilled to be included in the Hang Seng Hong Kong-Listed Biotech Index. This inclusion will not only elevate the company's profile among a broader spectrum of investors, but also create opportunities for our customers, partners, and investors to engage with Fangzhou Inc.'s innovative Internet healthcare solutions and be part of our mission to enhance healthcare accessibility and delivery."
方舟的董事长兼首席执行官谢芳敏表示："我们很高兴被纳入恒生香港上市生物科技指数。这一纳入不仅将提升公司在更广泛投资者中的知名度，还将为我们的客户、合作伙伴和投资者创造与方舟健客的创新互联网医疗保健解决方案互动的机会，并成为我们提升医疗保健可及性和服务能力使命的一部分。"
Fangzhou has been listed on the main board of the Hong Kong Stock Exchange since July 2024. As a pioneer in the Internet hospital sector, the Company is focused on chronic disease management and providing tailored medical care and precision medicine for a growing population of chronic disease patients.
方舟自2024年7月起已在香港股票交易所的主板上市。作为互联网医院行业的先驱，公司专注于慢性病管理，提供量身定制的医疗保健和精准医学，以服务日益增长的慢性病患者群体。
About Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO")
关于恒生香港上市生物科技指数（"HSHKBIO"）
In 2019 HSIL launched the Hang Seng Hong Kong Listed Biotech Index, which reflects the overall performance of biotech companies that are listed in Hong Kong, including stocks listed through Chapter 18A of the Listing Rules of Stock Exchange of Hong Kong Limited. HSHKBIO includes the 50 largest companies that are classified as "Biotechnology", "Pharmaceuticals", and "Medical Devices" in the Hang Seng Industry Classification System ("HSICS").
2019年，HSIL推出了恒生香港上市生物科技指数，该指数反映在香港上市的生物科技公司的整体表现，包括通过香港联合交易所上市规则第18A章上市的股票。HSHKBIO包括在恒生行业分类系统（"HSICS"）中被归类为"生物技术"、"制药"和"医疗设备"的50家公司。
About Fangzhou Inc.
关于方舟健客(临时代码)。
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit .
方舟健客(临时代码)（06086.HK）是中国领先的在线慢性病管理平台。截止到2024年6月30日，平台上拥有4560万注册用户和217,000名注册医生，公司为日益增长的慢性病患者提供定制的医疗保健和精准医疗服务。更多详情，请访问。
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
媒体联系
如需进一步询问或面试，请联系方式：
赵星伟 公共关系副主任
邮箱: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
免责声明：本新闻稿包含前瞻性声明。实际结果可能因各种因素与预期存在重大差异。提醒读者不要过于依赖这些声明。
